Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care

NCT ID: NCT01816841

Last Updated: 2020-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-11

Study Completion Date

2019-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial studies direct visual fluorescence in finding oral cancer in high-risk patients and patients undergoing routine dental care. Diagnostic procedures, such as direct visual fluorescence, may help find and diagnose oral cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To assess the diagnostic benefit of the VELscope (direct visual fluorescence) inspection in oral examination.

II. Efficacy of the VELscope in identifying dysplastic (premalignant) and malignant oral mucosal lesions and in discriminating these lesions from common benign tissue changes.

III. Accuracy of clinical judgment versus VELscope findings. IV. Ability of the VELscope to identify lesions or extent of lesions beyond what is clinically apparent.

OUTLINE:

Patients undergo conventional oral examination (COE) followed by direct visual fluorescence examination (DVFE). Patients with tissue abnormalities found by COE or DVFE undergo scalpel biopsy within 2 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lip and Oral Cavity Squamous Cell Carcinoma Oral Cavity Verrucous Carcinoma Stage 0 Lip and Oral Cavity Cancer Tongue Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic (COE and DVFE)- Arm I

Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.

Group Type EXPERIMENTAL

fluorescence imaging

Intervention Type PROCEDURE

Undergo DVFE

biopsy

Intervention Type PROCEDURE

Undergo scalpel biopsy

examination

Intervention Type PROCEDURE

Undergo COE

Arm II - Comparison of surgical margins using COE vs. DVFE

Comparison of surgical margins using COE vs. DVFE

Group Type EXPERIMENTAL

fluorescence imaging

Intervention Type PROCEDURE

Undergo DVFE

biopsy

Intervention Type PROCEDURE

Undergo scalpel biopsy

examination

Intervention Type PROCEDURE

Undergo COE

Comparison of surgical margins by COE vs. DVFE

Intervention Type PROCEDURE

Surgical margin determination using DVFE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluorescence imaging

Undergo DVFE

Intervention Type PROCEDURE

biopsy

Undergo scalpel biopsy

Intervention Type PROCEDURE

examination

Undergo COE

Intervention Type PROCEDURE

Comparison of surgical margins by COE vs. DVFE

Surgical margin determination using DVFE

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

biopsies Exam Medical Assessment Medical Exam Medical Examination Medical Inspection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIGH-RISK POPULATION:
* 33 consecutive consenting patients presenting to The Ohio State University James Cancer Hospital Otolaryngology Department with a suspicious oral lesion or prior biopsy-confirmed epithelial dysplasia (mild, moderate, severe), carcinoma in situ (CIS), or squamous cell carcinoma (SCC) will be recruited; adult patients presenting for initial evaluation for treatment planning and/or presenting for follow-up appointments monitoring for recurrence will be eligible to participate
* GENERAL POPULATION:
* 250 consecutive consenting patients presenting to The Ohio State University College of Dentistry for routing dental care will be recruited; adult patients presenting to the screening clinic for initial oral evaluation will be eligible to participate
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ohio State University Comprehensive Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kristin McNamara

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kristin McNamara, DDS, MS

Role: PRINCIPAL_INVESTIGATOR

Ohio State University Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

Columbus, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2012-02017

Identifier Type: REGISTRY

Identifier Source: secondary_id

OSU-08095

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Non-invasive Methods for Oral Cancer Screening
NCT07249437 ACTIVE_NOT_RECRUITING
NBI in Oral Cavity Cancer
NCT04398121 COMPLETED